The Telegraph reports that UK regulators gave CRISPR Therapeutics the go-ahead for its beta thalassemia clinical trial.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
CRISPR Therapeutics is moving toward clinical trials for beta thalassemia and sickle cell disease treatments, according to Wired.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
The firm will use MaxCyte's cell transfection platform to edit hematopoietic stem cells with CRISPR/Cas9 in hemoglobinopathy and SCID.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.
Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.
In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.